Project Grant R44HL178137
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$1.2M
Federal Agency
National Heart Lung and Blood Institute
Awardee
Pranions, Inc. (UL23TL5VZFN3)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Iowa, USA
Similar Awards
This $256,000 National Science Foundation SBIR Phase I Project Grant to Airomatix, Inc. supports the development of a portable oxygen concentrator capable of producing breathable oxygen at higher flow rates than current models. The concentrator utilizes a novel photocatalytic reaction to separate oxygen from ambient air and store it in a chemical solution. It will then release oxygen on demand through a temperature-controlled reaction. During the one-year period of performance ending March 2023,...
This STTR Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $294,063 to Biomembretics, Inc. to develop and demonstrate a high-volume manufacturing technology for microfluidic oxygenators for extracorporeal membrane oxygenation (ECMO) to treat respiratory failure. The project aims to advance a bioinspired microfluidic oxygenator technology that can safely and effectively oxygenate blood, addressing limitations of the...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,107,276 to Lasarrus Clinic And Research Center Inc. to develop a mobile health system for remote monitoring of patients with Chronic Obstructive Pulmonary Disease (COPD). The project aims to enhance patient adherence to remote monitoring and early symptom recognition, in order to reduce COPD readmissions and healthcare costs. The system utilizes a wearable...
The federal Project Grant award R01HL175892, funded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate new technology for accurate, rapid, point-of-care, and high-frequency blood gas analysis. The $735,939 award supports two key objectives: 1) creating a miniaturized and automated device that attaches to an arterial catheter to enable direct sampling and immediate blood gas analysis at the bedside,...
This $715,110 Project Grant, awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) on February 1, 2025, supports the preclinical evaluation of a novel peptide-amphiphile derived toroidal oxygen carrier. The goal is to design and optimize a "blood substitute prototype" based on a deformable nanoparticle that encapsulates hemoglobin and incorporates mechanisms to control oxygen binding and release. Key aspects include computational...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $1,160,157 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Liberandum Technologies, Inc. to develop and test a bidirectional synchronous flow-controlled ventilation system called "VentSafe" to improve oxygenation and ventilation in patients with Acute Respiratory Distress Syndrome (ARDS). The goal of this Phase 1 Small Business Innovation Research (SBIR) project is to overcome the limitations of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $499,966 to Koronis Biomedical Technologies Corp. (KBT) to commercialize a low-cost, portable device using the Forced Oscillation Technique (FOT) for respiratory assessment. The proposed FOT device requires minimal patient effort and skill, making it suitable for occupational health screening, physician office use, and home...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $842,408 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Inspire RX LLC, a start-up company based in Ann Arbor, Michigan. The goal of this 18-month project is to refine and further evaluate Inspire RX's "Aerosolve Biohelmet", a personal negative pressure device capable of preventing the spread of aerosolized pathogens while enabling non-invasive oxygen therapies for patients with highly...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $604,750 SBIR Phase I project grant (CFDA 93.837 - Cardiovascular Diseases Research) to Scientific Horizons Consulting LLC to develop a novel inhalation device and pulmonary delivery platform for anti-inflammatory agents to manage pain associated with chronic obstructive pulmonary disease (COPD). The project aims to investigate the feasibility of aerosolizing and delivering corticosteroids and non-steroidal anti-inflammatory drugs...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,530 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Spinhance LLC, a for-profit limited liability company located in Rydal, Pennsylvania. The grant aims to design, build, and evaluate a novel cardiopulmonary imaging device for continuous administration of the magnetic resonance imaging (MRI) contrast agent hyperpolarized xenon-129. This system is intended to support a new paradigm for...